Herantis Pharma Invitation To 1H 2023 Report On August 24, 2023 Eng
Kurs
+2,88%
Likviditet
0,00 MEUR
Prenumeration
Kalender
| Tid* | ||
| 2025-08-21 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-04-24 | N/A | Årsstämma |
| 2025-03-06 | 07:00 | Bokslutskommuniké 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-25 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2024-04-24 | - | Årsstämma |
| 2024-03-06 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Extra Bolagsstämma 2023 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-21 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2023-04-20 | - | Årsstämma |
| 2023-03-02 | - | Bokslutskommuniké 2022 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-22 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2022-04-21 | - | Årsstämma |
| 2022-03-03 | - | Bokslutskommuniké 2021 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-16 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2021-04-15 | - | Årsstämma |
| 2021-03-03 | - | Bokslutskommuniké 2020 |
| 2020-12-02 | - | Extra Bolagsstämma 2020 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-09 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2020-04-08 | - | Årsstämma |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-08-28 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-12 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2019-04-11 | - | Årsstämma |
| 2019-03-12 | - | Extra Bolagsstämma 2019 |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-08-29 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-12 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2018-04-11 | - | Årsstämma |
| 2018-03-02 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Extra Bolagsstämma 2017 |
| 2017-08-29 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-12 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2017-04-11 | - | Årsstämma |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-12 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2016-04-11 | - | Årsstämma |
| 2016-02-25 | - | Bokslutskommuniké 2015 |
| 2015-08-19 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-10 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2015-04-09 | - | Årsstämma |
| 2015-02-27 | - | Bokslutskommuniké 2014 |
| 2014-04-23 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-05 | - | Bokslutskommuniké 2013 |
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Herantis Pharma Plc | Press Release | August 14, 2023 at 13:00:00 EEST
Herantis Pharma Plc, Press Release, August 14 2023, at 13:00 EEST
Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease, today announced that the company will release 1H 2023 Report on Thursday, August 24, 2023, at 08:00 EEST/ 07:00 CEST.
Members of the Herantis’ Management team will hold a live webinar to provide more details on the 1H 2023 Report with a live Q&A session (in English) for investors, analysts, and media at 10:00 EEST / 9:00 CEST on the same date.
Please join the webinar a few minutes in advance.
Registration details: Herantis’ 1H 2023 Report Webinar
Registration is required for this event. To register for this event, you need a Zoom account. After registering, you will receive a confirmation email containing information about joining the webinar.
Questions can be submitted throughout the webcast event.
Following the webcast of the live call, a recording will be available on Herantis Pharma’s website: https://herantis.com/news-events/video-presentations/
Contacts
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225
About Us
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected by the end of 2023.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com